{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:50:01Z","timestamp":1793829001466,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K07428"],"award-info":[{"award-number":["JP21K07428"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K07508"],"award-info":[{"award-number":["JP22K07508"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22dk0207055h0002"],"award-info":[{"award-number":["22dk0207055h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer\u2019s disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential tools for predicting abnormal pathological protein accumulation. We aimed to investigate the association between AD-related plasma biomarkers and cognitive decline in PD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Plasma biomarkers were measured in 70 PD patients (49 with nondemented Parkinson\u2019s disease (PDND) and 21 with Parkinson\u2019s disease dementia (PDD)) and 38 healthy controls (HCs) using a single-molecule array. The study evaluated (1) the correlation between plasma biomarkers and clinical parameters, (2) receiver operating characteristic curves and areas under the curve to evaluate the discrimination capacity of plasma biomarkers among groups, and (3) a generalized linear model to analyze associations with Addenbrooke\u2019s Cognitive Examination-Revised and Montreal Cognitive Assessment-Japanese version scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups. Plasma beta-amyloid 42\/40 and pholphorylated-tau181 indicated AD pathology in the PDD group, but plasma beta-amyloid 42\/40 was increased in the PDND group compared with HCs and decreased in the PDD group compared with the PDND group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AD-related plasma biomarkers may predict cognitive decline in PD and uncover underlying mechanisms suggesting astrocytic pathologies related to cognitive decline in PD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11875-z","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T13:01:35Z","timestamp":1690030895000},"page":"5461-5474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease"],"prefix":"10.1007","volume":"270","author":[{"given":"Yasuaki","family":"Mizutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ohdake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harutsugu","family":"Tatebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8553-8536","authenticated-orcid":false,"given":"Hirohisa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"issue":"s1","key":"11875_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloemd BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8(s1):S3\u2013S8","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"11875_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/0891988712464823","volume":"25","author":"I Leroi","year":"2012","unstructured":"Leroi I, McDonald K, Pantula H, Harbishettar V (2012) Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 25(4):208\u2013214. https:\/\/doi.org\/10.1177\/0891988712464823","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"11875_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120077","volume":"432","author":"E Severiano","year":"2022","unstructured":"Severiano E, Sousa C, Alarc\u00e3o J, Martins IP, Ferreira JJ (2022) Frequency of dementia in Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Sci 432:120077. https:\/\/doi.org\/10.1016\/j.jns.2021.120077","journal-title":"J Neurol Sci"},{"issue":"3","key":"11875_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","volume":"23","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh MN, Adler CH, Lahti TJ et al (2009) Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 23(3):295\u2013297. https:\/\/doi.org\/10.1097\/WAD.0b013e31819c5ef4","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"11875_CR5","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","volume":"54","author":"HI Hurtig","year":"2000","unstructured":"Hurtig HI, Trojanowski JQ, Galvin J et al (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson\u2019s disease. Neurology 54(10):1916\u20131921. https:\/\/doi.org\/10.1212\/WNL.54.10.1916","journal-title":"Neurology"},{"issue":"1","key":"11875_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM et al (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7(1):47. https:\/\/doi.org\/10.1038\/s41572-021-00280-3","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"11875_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27(6):954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"issue":"4","key":"11875_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N et al (2023) Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement 19(4):1403\u20131414. https:\/\/doi.org\/10.1002\/alz.12787","journal-title":"Alzheimers Dement"},{"issue":"17","key":"11875_CR9","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V et al (2019) High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93(17):e1647\u2013e1659. https:\/\/doi.org\/10.1212\/WNL.0000000000008081","journal-title":"Neurology"},{"issue":"3","key":"11875_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26(3):379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"issue":"1","key":"11875_CR11","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12(1):3400. https:\/\/doi.org\/10.1038\/s41467-021-23620-z","journal-title":"Nat Commun"},{"issue":"11","key":"11875_CR12","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R et al (2021) Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144(11):3505\u20133516. https:\/\/doi.org\/10.1093\/brain\/awab223","journal-title":"Brain"},{"key":"11875_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.parkreldis.2022.05.020","volume":"105","author":"J Pagonabarraga","year":"2022","unstructured":"Pagonabarraga J, P\u00e9rez-Gonz\u00e1lez R, Bejr-kasem H et al (2022) Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson\u2019s disease. Parkinsonism Relat Disord 105:132\u2013138. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.05.020","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"11875_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","volume":"9","author":"Y Tang","year":"2023","unstructured":"Tang Y, Han L, Li S et al (2023) Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Parkinsons Dis 9(1):23. https:\/\/doi.org\/10.1038\/s41531-023-00447-7","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"11875_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349\u2013356. https:\/\/doi.org\/10.1002\/mds.24893","journal-title":"Mov Disord"},{"issue":"12","key":"11875_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22(12):1689\u20131707. https:\/\/doi.org\/10.1002\/mds.21507","journal-title":"Mov Disord"},{"issue":"3","key":"11875_CR17","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3233\/JPD-202097","volume":"10","author":"Y Tang","year":"2020","unstructured":"Tang Y, Liang X, Han L et al (2020) Cognitive function and quality of life in Parkinson\u2019s disease: a cross-sectional study. J Parkinsons Dis 10(3):1209\u20131216. https:\/\/doi.org\/10.3233\/JPD-202097","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"11875_CR18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"issue":"1","key":"11875_CR19","doi-asserted-by":"publisher","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"YS Lin","year":"2018","unstructured":"Lin YS, Lee WJ, Wang SJ, Fuh JL (2018) Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 8(1):17368. https:\/\/doi.org\/10.1038\/s41598-018-35766-w","journal-title":"Sci Rep"},{"issue":"16","key":"11875_CR20","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 22(16):2314\u20132324. https:\/\/doi.org\/10.1002\/mds.21844","journal-title":"Mov Disord"},{"issue":"1","key":"11875_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000336909","volume":"2","author":"KH dos Santos Kawata","year":"2012","unstructured":"dos Santos Kawata KH, Hashimoto R, Nishio Y et al (2012) A validation study of the Japanese Version of the Addenbrooke\u2019s Cognitive Examination-Revised. Dement Geriatr Cogn Dis Extra 2(1):29\u201337. https:\/\/doi.org\/10.1159\/000336909","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"11","key":"11875_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/gps.1610","volume":"21","author":"E Mioshi","year":"2006","unstructured":"Mioshi E, Dawson K, Mitchell J et al (2006) The Addenbrooke\u2019s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21(11):1078\u20131085. https:\/\/doi.org\/10.1002\/gps.1610","journal-title":"Int J Geriatr Psychiatry"},{"issue":"15","key":"11875_CR23","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-Sponsored Revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"issue":"11","key":"11875_CR24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","volume":"55","author":"B Dubois","year":"2000","unstructured":"Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55(11):1621\u20131626. https:\/\/doi.org\/10.1212\/WNL.55.11.1621","journal-title":"Neurology"},{"issue":"4","key":"11875_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x","journal-title":"J Am Geriatr Soc"},{"issue":"15","key":"11875_CR26","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25(15):2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"issue":"3","key":"11875_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and safinamide. Mov Disord Clin Pract 7(3):343\u2013345. https:\/\/doi.org\/10.1002\/mdc3.12921","journal-title":"Mov Disord Clin Pract"},{"issue":"6","key":"11875_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","volume":"38","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang KKW (2015) Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38(6):364\u2013374. https:\/\/doi.org\/10.1016\/j.tins.2015.04.003","journal-title":"Trends Neurosci"},{"issue":"8","key":"11875_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/antiox8080265","volume":"8","author":"A Rizor","year":"2019","unstructured":"Rizor A, Pajarillo E, Johnson J et al (2019) Astrocytic oxidative\/nitrosative stress contributes to parkinson\u2019s disease pathogenesis: the dual role of reactive astrocytes. Antioxidants 8(8):265. https:\/\/doi.org\/10.3390\/antiox8080265","journal-title":"Antioxidants"},{"issue":"1","key":"11875_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40478-022-01468-8","volume":"10","author":"MF Altay","year":"2022","unstructured":"Altay MF, Liu AKL, Holton JL et al (2022) Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders. Acta Neuropathol Commun 10(1):163. https:\/\/doi.org\/10.1186\/s40478-022-01468-8","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"11875_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S et al (2019) Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis 67(2):481\u2013488. https:\/\/doi.org\/10.3233\/JAD-180325","journal-title":"J Alzheimers Dis"},{"issue":"Pt 6","key":"11875_CR32","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/brain\/awv104","volume":"138","author":"J Gratwicke","year":"2015","unstructured":"Gratwicke J, Jahanshahi M, Foltynie T (2015) Parkinson\u2019s disease dementia: a neural networks perspective. Brain 138(Pt 6):1454\u20131476. https:\/\/doi.org\/10.1093\/brain\/awv104","journal-title":"Brain"},{"issue":"11","key":"11875_CR33","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S1474-4422(06)70600-7","volume":"5","author":"P Calabresi","year":"2006","unstructured":"Calabresi P, Picconi B, Parnetti L, Di FM (2006) Personal View A convergent model for cognitive dysfunctions in Parkinson\u2019s disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 5(11):974\u2013983. https:\/\/doi.org\/10.1016\/S1474-4422(06)70600-7","journal-title":"Lancet Neurol"},{"issue":"13","key":"11875_CR34","doi-asserted-by":"publisher","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, Van Rumund A, Oeckl P et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92(13):e1479\u2013e1486. https:\/\/doi.org\/10.1212\/WNL.0000000000007179","journal-title":"Neurology"},{"issue":"1","key":"11875_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu L, Rota S, Hye A et al (2022) Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. NPJ Parkinsons Dis 8(1):154. https:\/\/doi.org\/10.1038\/s41531-022-00384-x","journal-title":"NPJ Parkinsons Dis"},{"key":"11875_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2022.06.004","volume":"101","author":"YY Wong","year":"2022","unstructured":"Wong YY, Wu CY, Yu D et al (2022) Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: a systematic review and meta-analysis. Parkinsonism Relat Disord 101:119\u2013128. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.06.004","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"11875_CR37","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","volume":"36","author":"WW Aamodt","year":"2021","unstructured":"Aamodt WW, Waligorska T, Shen J et al (2021) Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov Disord 36(12):2945\u20132950. https:\/\/doi.org\/10.1002\/mds.28779","journal-title":"Mov Disord"},{"key":"11875_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577662","volume":"358","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Yang B, Wang F et al (2021) Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson\u2019s disease. J Neuroimmunol 358:577662. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577662","journal-title":"J Neuroimmunol"},{"issue":"1","key":"11875_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","volume":"15","author":"A Su Lyn Ng","year":"2020","unstructured":"Su Lyn Ng A, Jayne Tan Y, Cui Wen Yong A et al (2020) Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease. Mol Neurodegener 15(1):33. https:\/\/doi.org\/10.1186\/s13024-020-00385-5","journal-title":"Mol Neurodegener"},{"issue":"1\u20132","key":"11875_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0006-8993(99)01848-x","volume":"843","author":"K Arima","year":"1999","unstructured":"Arima K, Hirai S, Sunohara N et al (1999) Cellular co-localization of phosphorylated tau-and NACPra-synuclein-epitopes in Lewy bodies in sporadic Parkinson\u2019s disease and in dementia with Lewy bodies. Brain Res 843(1\u20132):53\u201361. https:\/\/doi.org\/10.1016\/s0006-8993(99)01848-x","journal-title":"Brain Res"},{"issue":"10","key":"11875_CR41","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, Nalls MA, Hallgr\u00edmsd\u00f3ttir IB et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet 49(10):1511\u20131516. https:\/\/doi.org\/10.1038\/ng.3955","journal-title":"Nat Genet"},{"issue":"7691","key":"11875_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL et al (2018) High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554(7691):249\u2013254. https:\/\/doi.org\/10.1038\/nature25456","journal-title":"Nature"},{"issue":"2","key":"11875_CR43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mds.29295","volume":"38","author":"K Baik","year":"2023","unstructured":"Baik K, Kim HR, Park M et al (2023) Effect of amyloid on cognitive performance in Parkinson\u2019s disease and dementia with Lewy bodies. Mov Disord 38(2):278\u2013285. https:\/\/doi.org\/10.1002\/mds.29295","journal-title":"Mov Disord"},{"key":"11875_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.805953","volume":"16","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Han X et al (2022) A panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes. Front Neurosci 16:805953. https:\/\/doi.org\/10.3389\/fnins.2022.805953","journal-title":"Front Neurosci"},{"issue":"3","key":"11875_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/S12640-016-9644-2","volume":"30","author":"DKY Chan","year":"2016","unstructured":"Chan DKY, Braidy N, Xu YH et al (2016) Interference of \u03b1-synuclein uptake by monomeric \u03b2-amyloid1-40 and potential core acting site of the interference. Neurotox Res 30(3):479\u2013485. https:\/\/doi.org\/10.1007\/S12640-016-9644-2","journal-title":"Neurotox Res"},{"key":"11875_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","volume":"12","author":"NC Chen","year":"2020","unstructured":"Chen NC, Chen HL, Li SH et al (2020) Plasma levels of \u03b1-synuclein, a\u03b2-40 and t-tau as biomarkers to predict cognitive impairment in Parkinson\u2019s disease. Front Aging Neurosci 12:112. https:\/\/doi.org\/10.3389\/fnagi.2020.00112","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"11875_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41531-023-00481-5","volume":"9","author":"Y Guo","year":"2023","unstructured":"Guo Y, Shen XN, Huang SY et al (2023) Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy. NPJ Parkinsons Dis 9(1):40. https:\/\/doi.org\/10.1038\/s41531-023-00481-5","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"11875_CR48","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s10072-017-3088-1","volume":"38","author":"X Hu","year":"2017","unstructured":"Hu X, Yang Y, Gong D (2017) Changes of cerebrospinal fluid A\u03b242, t-tau, and p-tau in Parkinson\u2019s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis. Neurol Sci 38(11):1953\u20131961. https:\/\/doi.org\/10.1007\/s10072-017-3088-1","journal-title":"Neurol Sci"},{"issue":"1","key":"11875_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40478-020-01083-5","volume":"8","author":"A Kouli","year":"2020","unstructured":"Kouli A, Camacho M, Allinson K, Williams-Gray CH (2020) Neuroinflammation and protein pathology in Parkinson\u2019s disease dementia. Acta Neuropathol Commun 8(1):211. https:\/\/doi.org\/10.1186\/s40478-020-01083-5","journal-title":"Acta Neuropathol Commun"},{"key":"11875_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51768","author":"KAQ Cousins","year":"2023","unstructured":"Cousins KAQ, Irwin DJ, Chen-Plotkin A et al (2023) Plasma GFAP associates with secondary Alzheimer\u2019s pathology in Lewy body disease. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.51768","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"11875_CR51","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1212\/WNL.0000000000200344","volume":"99","author":"PS Myers","year":"2022","unstructured":"Myers PS, O\u2019Donnell JL, Jackson JJ et al (2022) Proteinopathy and longitudinal cognitive decline in Parkinson disease. Neurology 99(1):e66\u2013e76. https:\/\/doi.org\/10.1212\/WNL.0000000000200344","journal-title":"Neurology"},{"issue":"7","key":"11875_CR52","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.26191","volume":"30","author":"M Petrou","year":"2015","unstructured":"Petrou M, Dwamena BA, Foerster BR et al (2015) Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic review. Mov Disord 30(7):928\u2013935. https:\/\/doi.org\/10.1002\/mds.26191","journal-title":"Mov Disord"},{"issue":"2","key":"11875_CR53","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3233\/JAD-190323","volume":"70","author":"G Palermo","year":"2019","unstructured":"Palermo G, Tommasini L, Aghakhanyan G et al (2019) Clinical correlates of cerebral amyloid deposition in Parkinson\u2019s disease dementia: evidence from a PET study. J Alzheimers Dis 70(2):595\u2013607. https:\/\/doi.org\/10.3233\/JAD-190323","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"11875_CR54","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1474","volume":"9","author":"AA Kehagia","year":"2010","unstructured":"Kehagia AA, Robbins FRSTW, Robbins TW et al (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson\u2019s disease. Lancet Neurol 9(12):1200\u20131213. https:\/\/doi.org\/10.1016\/S1474","journal-title":"Lancet Neurol"},{"key":"11875_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.03.021","author":"M Carceles-Cordon","year":"2023","unstructured":"Carceles-Cordon M, Weintraub D, Chen-Plotkin AS (2023) Cognitive heterogeneity in Parkinson\u2019s disease: a mechanistic view. Neuron. https:\/\/doi.org\/10.1016\/j.neuron.2023.03.021","journal-title":"Neuron"},{"key":"11875_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105385","author":"E Bayram","year":"2023","unstructured":"Bayram E, Batzu L, Tilley B et al (2023) Clinical trials for cognition in Parkinson\u2019s disease: Where are we and how can we do better? Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105385","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11875-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11875-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11875-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:05:08Z","timestamp":1697274308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11875-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["11875"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11875-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"13 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All participants provided written informed consent before participation, as well as opt-out consent. This study was approved by the ethics committee of Fujita Health University Hospital and was conducted in accordance with the regulations of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}